X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fulford India with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs CIPLA - Comparison Results

FULFORD INDIA    Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA CIPLA FULFORD INDIA/
CIPLA
 
P/E (TTM) x 398.8 33.3 1,198.4% View Chart
P/BV x 6.2 2.9 214.4% View Chart
Dividend Yield % 0.1 0.6 14.5%  

Financials

 FULFORD INDIA   CIPLA
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
CIPLA
Mar-18
FULFORD INDIA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs942663 142.1%   
Low Rs450479 93.9%   
Sales per share (Unadj.) Rs691.4189.0 365.8%  
Earnings per share (Unadj.) Rs11.517.6 65.1%  
Cash flow per share (Unadj.) Rs15.434.0 45.1%  
Dividends per share (Unadj.) Rs2.003.00 66.7%  
Dividend yield (eoy) %0.30.5 54.7%  
Book value per share (Unadj.) Rs380.0176.7 215.0%  
Shares outstanding (eoy) m3.90805.12 0.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.03.0 33.3%   
Avg P/E ratio x60.732.5 187.1%  
P/CF ratio (eoy) x45.316.8 270.0%  
Price / Book Value ratio x1.83.2 56.7%  
Dividend payout %17.417.1 102.3%   
Avg Mkt Cap Rs m2,714459,724 0.6%   
No. of employees `0000.423.6 1.9%   
Total wages/salary Rs m50526,901 1.9%   
Avg. sales/employee Rs Th6,073.06,446.1 94.2%   
Avg. wages/employee Rs Th1,137.41,139.4 99.8%   
Avg. net profit/employee Rs Th100.7600.0 16.8%   
INCOME DATA
Net Sales Rs m2,696152,193 1.8%  
Other income Rs m1253,577 3.5%   
Total revenues Rs m2,822155,769 1.8%   
Gross profit Rs m-4628,264 -0.2%  
Depreciation Rs m1513,228 0.1%   
Interest Rs m101,142 0.8%   
Profit before tax Rs m5417,470 0.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m102,501 0.4%   
Profit after tax Rs m4514,166 0.3%  
Gross profit margin %-1.718.6 -9.3%  
Effective tax rate %17.714.3 123.5%   
Net profit margin %1.79.3 17.8%  
BALANCE SHEET DATA
Current assets Rs m1,738108,141 1.6%   
Current liabilities Rs m54538,322 1.4%   
Net working cap to sales %44.345.9 96.5%  
Current ratio x3.22.8 113.1%  
Inventory Days Days4897 50.0%  
Debtors Days Days474 5.8%  
Net fixed assets Rs m12109,411 0.0%   
Share capital Rs m391,610 2.4%   
"Free" reserves Rs m1,443140,682 1.0%   
Net worth Rs m1,482142,292 1.0%   
Long term debt Rs m036,621 0.0%   
Total assets Rs m2,077228,606 0.9%  
Interest coverage x6.716.3 41.2%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.30.7 195.0%   
Return on assets %2.66.7 39.0%  
Return on equity %3.010.0 30.3%  
Return on capital %4.310.0 43.2%  
Exports to sales %032.8 0.0%   
Imports to sales %24.50-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs m659NA-   
Fx inflow Rs m1751,691 0.0%   
Fx outflow Rs m67321,033 3.2%   
Net fx Rs m-65630,658 -2.1%   
CASH FLOW
From Operations Rs m9014,628 0.6%  
From Investments Rs m105-8,540 -1.2%  
From Financial Activity Rs m-14-3,855 0.4%  
Net Cashflow Rs m1812,431 7.4%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 75.0 20.8 360.6%  
Indian inst/Mut Fund % 3.8 12.2 31.1%  
FIIs % 0.1 23.7 0.4%  
ADR/GDR % 0.0 1.1 -  
Free float % 21.2 26.2 80.9%  
Shareholders   4,783 161,166 3.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  MERCK LTD  GSK PHARMA  

Compare FULFORD INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks ahead of Election Results; Realty Stocks Plummet(Closing)

Indian share markets settled around 2% lower today following a sell-off in the global markets and due to uncertainty over the outcome of state assembly elections tomorrow.

Related Views on News

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA - PANACEA BIOTECH COMPARISON

COMPARE FULFORD INDIA WITH

MARKET STATS